Eli Lilly and Company shuffled some of its therapeutic area heads into new roles two years ago, and the company announced on 4 October that it is mixing up its leadership structure again now that EVP Mike Mason, president of Lilly Diabetes and Obesity, is set to retire at the end of 2023. Among the changes, chief scientific officer and president of Lilly Research Laboratories Daniel Skovronsky will take on the additional role of president of Lilly Immunology.
Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight
Moves Follow Recent Anti-Inflammatory Program Setbacks
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.
More from Leadership
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.